Planet Microcap Podcast | Microcap Investing Strategies

My guest on the show today is Cameron Reynolds, President and CEO of VolitionRx Limited (NYSE AMERICAN: VNRX). Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. While the company has been primarily focused on human diagnostics and monitoring, it also has a subsidiary focused on animal diagnostics and monitoring. Even though Volition's animal diagnostics and monitoring subsidiary is relatively new, the company recently announced a $28M deal with Heska Corporation for their low cost animal cancer screening and monitoring tests. I've known Volition for a long time, and want to chat with Cameron about: Animal diagnostics and monitoring subsidiary How this subsidiary fits with Volition's strategy moving forward Current status on their clinical trials for their blood tests What Ca